

From QTL to QTN

Identification of a Quantitative Trait Nucleotide Influencing Muscle Development and Fat Deposition in Pig

Anne-Sophie Van Laere

Veterinary Faculty

Department of Animal Breeding and Genetics

Uppsala

Doctoral thesis

Swedish University of Agricultural Sciences

Uppsala 2005

Acta Universitatis Agriculturae Sueciae

2005: 9

ISSN 1652-6880
ISBN 91-576-7008-0
© 2005 Anne-Sophie Van Laere, Uppsala
Tryck: SLU Service/Repro, Uppsala 2005

Abstract

Van Laere, A.S. 2004. From QTL to QTN. Identification of a Quantitative Trait Nucleotide Influencing Muscle Development and Fat Deposition in Pig. Doctor's dissertation.

ISSN:1652-6880, ISBN:91-576-7008-0

Most traits of economical importance in animal production are quantitative i.e. they are characterized by a continuous variation of phenotypic values. Examples for such traits are carcass weight, milk production and lean meat content. The phenotype of an animal for a quantitative trait depends on its genotype at several loci (called quantitative trait loci, QTL) as well as on environmental factors. Up to date, a large number of QTLs have been identified in farm animals by segregation analysis either within commercial populations or in crossbreed populations. Animal geneticists face now the challenge to identify the causative mutations lying behind these QTLs.

In this thesis, we report the identification of the causative mutation for a major QTL influencing muscle development, fat deposition and heart size in pig. Previous studies have mapped this locus to the distal end of pig chromosome 2p. Furthermore, they have hypothesized that the causative mutation(s) may lie in an element regulating the expression of insulin-like growth factor 2 (IGF2). Firstly, we sequenced the IGF2 region in the pig and made comparative sequence analysis with available human and mouse sequences. We then used an identity-by-descent approach and managed to pinpoint the causative mutation to a G→A transition located in an evolutionary conserved CpG island in IGF2 intron 3 (IGF2-intron3-G3070A). Subsequently, we used electrophoretic mobility shift assay and transient transfection experiments and showed that the QTN (quantitative trait nucleotide) abrogates the binding of a putative repressor. We completed our study by determining the core binding site of this transacting factor and by performing DNase I footprinting of the CpG island containing the QTN. In addition, we identified an IGF2 antisense transcript (IGF2-AS) and showed that its expression was also influenced by the QTN.

The discovery of mutations causing QTLs in farm animals opens great future prospects. Besides evident practical breeding interests there are also major scientific interests, as understanding the mechanism causing the QTL effects will broaden our general knowledge on how the genome operates.

Keywords: antisense transcript, CpG island, quantitative trait locus, quantitative trait nucleotide, repressor, *Sus scrofa*.

Author's address: Anne-Sophie Van Laere, Department of Animal Breeding and Genetics, SLU, BMC, Box 597, S-751 24 UPPSALA, Sweden. Email: Anne-Sophie.Van.Laere@bmc.uu.se

Contents

Introduction, 7

- I. Chromosomal location of *IGF2*, 8
- II. Effects of *IGF2*, 8
 - Receptors*, 8
 - Binding proteins*, 9
 - Biological actions*, 9
- III. Imprinting, 10
 - Definition*, 10
 - Transmission of imprints*, 10
 - (Epi)genetic characteristics of imprinted genes*, 11
 - Regulation of expression at the IGF2 locus*, 13

Aims of the thesis, 15

Methods, 16

- I. Transient transfection, 16
- II. Electrophoretic mobility shift assay, 16
- III. DNase I footprinting, 17

Results and discussion, 19

- I. Comparative sequence analysis of the *INS-IGF2-H19* gene cluster in pigs (Paper 1), 19
- II. A regulatory mutation in *IGF2* causes a major QTL effect on muscle growth in the pig (Paper 2), 20
- III. *IGF2* antisense transcript expression in porcine postnatal muscle is affected by a quantitative trait nucleotide in intron 3 (Paper 3), 22
- IV. Molecular Characterization of a Region in *IGF2* Intron 3 harbouring a Quantitative Trait Nucleotide affecting Muscle Growth in the Pig (Paper 4), 24

Future prospects, 26

References, 27

Acknowledgements, 31

Appendix

Papers I-IV

The present thesis is based on the following papers, which will be referred to by their Roman numerals:

- I. Amarger, V., Nguyen, M., Van Laere, A.S., Braunschweig, M., Nezer, C., Georges, M. & Andersson, L. 2002. Comparative sequence analysis of the INS-IGF2-H19 gene cluster in pigs. *Mammalian Genome* 13, 388-398.
- II. Van Laere, A.S., Nguyen, M., Braunschweig, M., Nezer, C., Collette, C., Moreau, L., Archibald, A.L., Haley, C.S., Buys, N., Tally, M., Andersson, G., Georges, M. & Andersson, L. 2003. A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig. *Nature* 425, 832-836.
- III. Braunschweig, M.H., Van Laere, A.S., Buys, N., Andersson, L. & Andersson, G. 2004. IGF2 antisense transcript expression in porcine postnatal muscle is affected by a quantitative trait nucleotide in intron 3. *Genomics* 84, 1021-1029.
- IV. Van Laere, A.S., Andersson, G., Kindmark, A. & Andersson, L. Molecular Characterization of a Region in *IGF2* Intron 3 harbouring a Quantitative Trait Nucleotide affecting Muscle Growth in the Pig. (Manuscript).

Papers I-III are reproduced by permission of the journals concerned.

Introduction

Most traits of economical importance in animal production are quantitative *i.e.* they are characterized by a continuous variation of phenotypic values. Examples for such traits are carcass weight, milk production and lean meat content. The phenotype of an animal for a quantitative trait depends on its genotype at several loci (called quantitative trait loci, QTL) as well as on environmental factors (Andersson, 2001). Up to date, a large number of QTLs have been identified in farm animals by segregation analysis either within commercial populations or in crossbreed populations. Animal geneticists face now the challenge to identify the causative mutations lying behind these QTLs. The major obstacle is the poor precision in the location of those loci. Indeed, the complex relation between genotype and phenotype complicates the detection of recombinants between markers and QTL as the genotype of an individual can only be determined by progeny testing. In addition, the nature of QTL mutations might complicate their identification. QTLs are not responsible for disorders but only for mild variation in phenotypic value and are therefore expected to be caused by a variant gene product or an altered gene expression rather than by a defect in gene product or in gene expression. The causative mutation(s) can hence be regulatory or structural and might be extremely difficult to distinguish from neutral linked mutations (Georges & Andersson, 1996).

During the last decades, overweight and metabolic disorders have been increasing in western countries. As a consequence, the demand on “lighter” more healthy products has also increased. This led the pig industry to select for animals with higher lean muscle and reduced fat deposition. This selection goes in opposite direction to the one occurring on wild boars. Indeed, natural selection favours animals that can store energy (*i.e.* fat), as those will be able to survive periods of starvation. A three-generation intercross was made between wild boars and Large White domestic pigs in an attempt to discover QTLs responsible for the differences in growth and fat deposition observed between those animals (Andersson *et al.*, 1994; Andersson-Eklund *et al.*, 1998). This successful approach led to the discovery of several QTLs, including one influencing muscle development, fat deposition and heart size. This locus maps to the distal end of pig chromosome 2p (SSC2p) and has the particularity of being imprinted (maternally silenced). Early studies (Jeon *et al.*, 1999; Nezer *et al.*, 1999) have suggested *IGF2* (insulin-like growth factor 2) as a candidate gene for this QTL because of:

- its chromosomal location,
- its paternal-specific expression,
- its effect on myogenesis.

I. Chromosomal location of *IGF2*

The chromosomal location of *IGF2* in pigs was unknown at the time the QTL was discovered. However, it was suspected to co-localize with the QTL because of its position in the human genome. Indeed, *IGF2* was known to map to human chromosome 11p15.5 and bidirectional chromosome painting had shown that HSA11pter-q13 corresponds to SSC2p (Goureau *et al.*, 1996). A FISH (fluorescent *in situ* hybridisation) experiment was consequently set up to confirm the assignment of *IGF2* to SSC2p. In this experiment, a porcine BAC clone containing *IGF2* was hybridized to porcine metaphase chromosomes and gave a consistent signal on the distal end of chromosome 2p (band 2p1.7) (Jeon *et al.*, 1999). This confirmed that *IGF2* and the QTL both mapped to the distal end of pig chromosome 2.

II. Effects of IGF-II

Insulin-like growth factor II (IGF-II) is a 67 amino acid-long, single chain polypeptide belonging to the insulin family. This family also includes insulin and insulin-like growth factor I (IGF-I). The genes coding for these three proteins are orthologs (i.e. they have evolved from a common ancestral gene) and are the result of two duplication events. The first duplication occurred approximately 600 million years ago and gave rise to insulin and a common ancestor for the two insulin-like growth factors. This ancestor then led to the genes coding for IGF-I and IGF-II after an additional duplication event that took place around 300 million years ago (Froesch *et al.*, 1985).

IGF-II and insulin show 47% sequence identity at the amino acid level. Furthermore, they have the same three-dimensional structure since they have the same three interchain disulphide bridges and hydrophobic core (O'Dell & Day, 1998).

Receptors

IGF-II exerts its biological effects through three receptors:

IGF-I receptor

The IGF-I receptor binds IGF-I with highest affinity but it binds also IGF-II (with 2-15 times lower affinity) and insulin (with 100-500 lower affinity). It is present in a large variety of tissues where it mediates most of the effects of both IGF-I and IGF-II (Cohick & Clemmons, 1993).

IGF-II receptor

The IGF-II receptor has a high affinity for IGF-II. It can also bind IGF-I but with a 100 to 500 times lower affinity and it does not bind insulin at all. This receptor is mainly known for its clearance role; hence, it internalizes IGF-II upon binding and transports it to the lysosomes for degradation (Jones & Clemmons, 1995). In addition, it has been demonstrated to mediate part of the physiological actions of IGF-II *e.g.* on myosarcoma cell motility (Minniti *et al.*, 1992) and on extravillous

trophoblast cell migration (McKinnon *et al.*, 2001). The IGF-II receptor possesses two binding sites for mannose-6-phosphate (Man-6-P) in addition to its IGF-II binding site and is therefore also known as cation-independent mannose-6-phosphate receptor. These Man-6-P sites mediate the transport of lysosomal enzymes from the Golgi apparatus to the pre-lysosomes and the endocytosis of ligands containing Man-6-P *e.g.* thyroglobulin.

Insulin receptor

The insulin receptor binds both insulin and IGF-II, but it has a ten times lower affinity for IGF-II compared to insulin. It was shown to mediate part of the growth promoting function of IGF-II in human and mouse fetus (Louvi, Accili & Efstratiadis, 1997). The insulin and IGF-I receptors are structurally highly similar heterotetrameric glycoproteins composed of two alpha and two beta subunits ($\alpha_2\beta_2$). Hybrid insulin/IGF-I receptors composed of one $\alpha\beta$ IGF-I half receptor and one $\alpha\beta$ insulin half receptor have even been found on cells expressing both types of receptors (Jones & Clemmons, 1995).

Binding Proteins

More than 99% of circulating IGFs are bound by Insulin-like Growth Factor Binding Proteins (IGFBP) (Dupont *et al.*, 2003). Up till now, six IGFBP (IGFBP1-6) have been described. They are characterized by conserved amino- and carboxy-terminal but each of them has a unique central domain. Their main role is to modulate the biological effects of the IGFs by (1) maintaining a reservoir of IGFs in circulation, (2) transporting IGFs across the capillary membrane, (3) localizing the IGFs to specific tissues, (4) modulating binding of the IGFs to their receptors and (5) prolonging the half-life of the IGFs (Wood, 1995). In addition, they have also been shown to have various IGF-independent actions *e.g.* as growth modulators (Mohan & Baylink, 2002).

Biological actions

IGF-II acts both through endocrine and autocrine / paracrine pathways and has been shown to:

- Promote feto-placental growth: IGF-II has metabolic, mitogenic and differentiative actions on a wide range of fetal tissues and on the placenta (Jones & Clemmons, 1995). Experiments using transgenic mice have proven that IGF-II is a potent fetal growth factor. DeChiara, Robertson & Efstratiadis (1990) showed, for example, that knockout *Igf2* mice weigh only 60% of the normal weight at birth.
- Promote both cell proliferation and cell differentiation. Hence, Florini and co-workers (1991) demonstrated that autocrine secretion of IGF-II plays a major role in skeletal muscle cell differentiation. Oksbjerg, Gondret & Vestergaard (2004) reported that, in muscle cells, the stimulation of proliferation and differentiation by the IGFs is concentration- and time-dependant.
- Prevent apoptosis: this has been shown *e.g.* in cultures of myoblast, neurons and oligodendrocytes (Jones & Clemmons, 1995)

- Mediate insulin-like effects *e.g.* on glucose and fat metabolism (Jones & Clemmons, 1995).
- Increase cell motility (and hence malignancy) in myosarcoma (Minniti *et al.*, 1992), to increase migration of extravillous trophoblastic cells (McKinnon *et al.*, 2001).

In addition, over-expression of IGF-II has been shown to cause cell hyperproliferation associated with tumour formation (Wood, 1995).

III. Imprinting

Definition

Genomic imprinting has been defined as “an epigenetic modification that is parental-origin specific, and/or preferential expression of a specific parental allele in somatic cells of the offspring” (Feinberg, Cui & Ohlsson, 2002). The term “epigenetic” literally means outside conventional genetics (Jaenisch & Bird, 2003); thus, epigenetic modifications are modifications of the chromatin (*e.g.* histone acetylation, DNA methylation) without modification of the DNA sequence (Wilkins & Haig, 2003). Those modifications are heritable through many cell divisions but can also be reset (at least in germline).

Transmission of imprints

The exact nature of the primary epigenetic modification(s) responsible for the establishment of imprinting is still unknown. Nevertheless, Li and co-worker’s (1993) study on knockout mice has proven that methylation is necessary at least for maintaining imprinting. The imprints causing parent-of-origin specific expression have to be reset at each generation in order to correspond to the germline of the new individual. Hence, imprints go through a three-step life cycle (Reik & Walter, 2001a):

Erasure

This first step occurs in the primordial germ cells. Imprints inherited from the parents are removed and DNA is totally unmethylated. Nuclear transplantation experiments in mouse have shown that *Igf2* is silenced at this stage whereas *H19* is expressed (Labosky *et al.*, 1994).

Establishment

The new imprints specific to the germline (oocyte or sperm) are set up at a late fetal stage in males and after birth in females. *De novo* methylation takes place and results in overall higher methylation in male germ cells than in oocytes.

Maintenance

The new imprints have to be transmitted to both daughter cells at mitoses. This is more challenging than it first appears as the new imprints have to resist the genome-wide demethylation occurring after fertilization and the *de novo* methylation taking place after implantation.

(Epi)genetic characteristics of imprinted genes

Clusters

Eighty percents of imprinted genes are found in clusters. Genes linked in the same cluster are believed to be co-regulated (Reik & Walter, 2001a), notably through Imprinting Control Regions (ICR). These are CpG-rich *cis*-acting elements that are found associated to approximately 50% of the known imprinted genes and are essential for the correct imprinting to occur (Fergusson-Smith & Surani, 2001). ICRs can be up to several kilobases long and are differentially methylated (usually the maternally-derived ICR is methylated) (Delaval & Feil, 2004).

CpG islands

CpG islands are not an exclusive characteristic of imprinted genes but imprinted genes are much more often associated with CpG islands than non-imprinted genes (88% versus 47% in mouse) (Reik & Walter, 2001a). Gardiner-Garden and Frommer (1987) defined CpG islands as DNA stretches fulfilling the three following criteria:

- length > 200 bp,
- G + C content > 50%,
- Observed CpG / Expected CpG > 0.6.

Direct repeats

The presence of tandem direct repeats associated to GC-rich sequences is a common characteristic among many imprinted genes. These repeats have been suggested to attract the methylation machinery by mimicking foreign DNA structure. Indeed, DNA methylation has been proposed to have evolved to protect the host against the spreading of transposons and endogenous retroviruses. The methylation and subsequent heterochromatization of the tandem repeats could lead to spreading of methylation to the nearby GC-rich region. Nevertheless, deletion experiments realized with *H19* transgenes have shown that the tandem repeats alone are not sufficient to cause allele-specific methylation (Reik & Walter, 2001a).

Except for their association with imprinted genes, the repeats themselves do not have much in common. Their sequence, number of repetitions, length, position relatively to the gene, position relatively to the CpG island or DMR (differentially methylated region) varies. Consequently, if they are involved in the acquisition and/or the maintenance of differential methylation they would probably act through their organization. This could be done by:

- Influencing the DNA secondary structure
- Being recognized by protein complexes, *e.g.* methyltransferase

DNA methylation

DNA methylation has been shown to be a key element to maintain imprinting (Brannan & Bartolomei, 1999; Tilghman, 1999). In eukaryotes, methylation occurs on the carbon at position 5 of cytosines found in CpG dinucleotides (and much more rarely in CpNpG trinucleotides) (Strachan & Read, 1999).



The resulting 5-methylcytosines are unstable and tend to deaminate into thymines. This phenomenon has resulted in a decrease of the frequency of CpG dinucleotides in the genome over time so that the actual observed frequency only corresponds to 23% and 19% of the expected frequency in human and mouse, respectively (Fazzari & Grealley, 2004).

The majority of known imprinted genes have been shown to contain differentially methylated regions (DMR). These CpG-rich regions can be methylated on the active or silenced allele and can contain various types of regulatory elements like enhancers, repressors and chromatin boundaries. Differential methylation results in allele-specific gene expression by modifying the protein-DNA interactions. Indeed, the addition of a methyl group to the cytosine modifies the aspect of the major groove of the DNA (which contains most of the DNA-protein recognition sites) (Constância *et al.*, 1998; Fazzari & Grealley, 2004) and can consequently:

- prevent binding of transcription factors,
- allow methyl CpG binding proteins (e.g. MeCP1, MeCP2) to bind. These proteins bind specifically to methylated DNA and mediate silencing through histone deacetylation and subsequent chromatin condensation (Jones, 1999; Jaenish & Bird, 2003).

Antisense transcripts

Fifteen percent of known imprinted genes have an antisense transcript. Amazingly, this antisense gene is also imprinted and (almost) always maternally silenced, whether the sense transcript is maternally or paternally expressed (Reik & Walter, 2001a). The hypothesis that the antisense transcript is important for the regulation of the sense gene was recently proven for Air (antisense Insulin-like growth factor 2 receptor) (Sleutels, Zwart & Barlow, 2002) and Kcnq1ot1 (antisense Kcnq1) (Thakur *et al.*, 2004).

It is amazing to notice that if (almost) all imprinted antisense genes are paternally transcribed, the majority of the DMRs are maternally methylated. Reik & Walter (2001b) have linked these observations to the fact that the genome-wide demethylation occurring after fertilization is active on the paternally inherited chromosomes but passive on the maternally inherited ones. Hence, they suggested that this active demethylation could be an attempt from the mother's side to remove paternal imprints. Paternal imprints would then have evolved towards another type of silencing mechanism *i.e.* antisense transcripts.

Asynchronous replication

Kitsberg and co-workers (1993) studied the timing of replication of imprinted genes by *in situ* hybridization to interphase nuclei. They showed that replication of imprinted genes is asynchronous and even allele-specific as the paternal allele always replicates before the maternal allele. Hence, Kitsberg and co-workers suggested that the different replication time is a necessary imprint to establish

allele-specific gene expression (*e.g.* by changing the accessibility of the DNA for methyltransferases).

Meiotic recombination

The observation that regions actively transcribed during gametogenesis are more prone to recombination led Thomas and Rothstein (1991) to the hypothesis that the sex-specific recombination frequencies observed at certain places of the genome might be caused by sex-specific gene expression *e.g.* imprinting. Paldi, Gyapay & Jami (1995) suggested that chromatin is organized in higher-order structures that are responsible for:

- Asynchronous replication.
- Different frequency of meiotic recombination between sexes: actively transcribed regions have a more “open” chromatin structure which allows more recombinations (possibly because enzymes initiating crossing-overs have a better access to the DNA).
- Imprinting: genes display allele-specific expression if:
 - o They have specific signals in their sequence.
 - o Modifying enzymes can access those signals in one sex but not in the other because of the different chromatin environment.

Regulation of expression at the IGF2 locus

IGF2 is part of a cluster of imprinted genes located on HSA11p15.5 (corresponding to SSC2p1.7). Two ICRs (imprinted control regions) regulate the imprinting of these genes. The first one, Kv ICR, controls the imprinting of the centromeric subcluster which contains *KCNQ1*, *KCNQ1OT1* and *CDKN1C*. The second one, *H19* ICR, is located 2-4 kb upstream of the *H19* promoter and controls imprinting at the telomeric subcluster which contains *H19* and *IGF2* (Du *et al.*, 2003). These two genes are reciprocally imprinted so that in most tissues *H19* is maternally expressed (Bartolomei, Zemel & Tilghman, 1991) and *IGF2* is paternally expressed (DeChiara, Robertson & Efstratiadis, 1991; Nezer *et al.*, 1999). Furthermore, Li *et al.* (1998) suggested that the human *H19* gene is an antagonist of *IGF2* expressivity in *trans*. The mechanisms controlling imprinting at the *IGF2-H19* domain are complex and appear to be tissue-specific. In the endoderm, expression of *IGF2* and *H19* depends on activation of their promoters by a set of shared enhancers located 3' of *H19* (Leighton *et al.*, 1995). On the maternal chromosome, the unmethylated *H19* ICR is bound by CCCTC-binding factors (CTCF). This creates a chromatin boundary which isolates the *IGF2* promoters from the endodermal enhancers and results in silencing of *IGF2* and expression of *H19*. On the paternal chromosome, methylation of the ICR prevents CTCF from binding which results in activation of the *IGF2* promoters by the endodermal-specific enhancers and *IGF2* transcription (Bell & Felsenfeld, 2000; Hark *et al.*, 2000; Kanduri *et al.*, 2000a, b). In addition, the methylated ICR directs methylation and subsequent silencing of the *H19* promoter (Srivastava *et al.*, 2000) (Figure 1). The situation appears to be more complex in mesodermal tissues. In addition to mesodermal-specific enhancers located 3' of *H19* (Ishihara *et al.*, 2000), a series of other control elements have also been found as *e.g.* a silencer located in DMR1 (*IGF2* intron 3) (Eden *et al.*, 2001) and a muscle-

specific silencer situated in the *IGF2-H19* intergenic region (Ainscough *et al.*, 2000).




Figure 1
Representation of the boundary model explaining imprinting at the *IGF2-H19* locus. The *H19* ICR is unmethylated on the maternal chromosome and is consequently

bound by CTCF. This creates a chromatin boundary that prevents the endodermal enhancers (represented as triangles) to activate *IGF2* expression. The promoter of *H19* is unmethylated and its expression can hence be activated by the endodermal enhancers. On the contrary, the *H19* ICR is methylated on the paternal chromosome (methyl groups are represented as stars). This methylation spreads to the *H19* promoter which becomes silenced. In addition CTCF cannot bind to the methylated ICR and the endodermal enhancers can activate transcription of *IGF2* (modified from Rand & Cedar, 2003).

At imprinted loci, the level of transcription of the transcribed allele is still controlled by transcription factors like at non-imprinted loci. Most information available on the regulation of *IGF2*'s four promoters (P1-4) (Sussenbach 1989; van Dijk *et al.*, 1991) comes from studies made in different human liver cell lines. Hence, promoter P1 has been shown to be activated by the ubiquitous transcription factor Sp1 (Rodenburg, Holthuisen & Sussenbach, 1997) and by the CCAAT/enhancer binding protein (C/EBP) (van Dijk. *et al.*, 1992). Promoters P3 and P4 have been shown to be regulated by the zinc finger transcription factors Egr-1 and WT1. These two proteins bind to the same DNA element but binding of Egr-1 results in transcriptional activation whereas binding of WT1 results in transcriptional repression (Bae *et al.*, 1999; Lee *et al.*, 1998). In addition, Rietveld *et al.* (1999) have demonstrated that transcription from promoter P3 responds to AP-2 binding so that overexpression of AP-2 results in activation of P3 in cells with low endogenous level of AP-2 and repression of P3 in cells with high endogenous level of AP-2. P3 has also been shown to be activated by the zinc finger oncogene PLAG1 (Zatkova *et al.*, 2004). Finally, Sp1 was shown to bind to promoter P4 and to cooperate with Egr-1 to mediate maximal activity of this promoter (Lee, Park & Lee, 2001). The regulation of *IGF2* transcription in skeletal muscle cells has been less studied and is poorly understood. However, Erbay *et al.* (2003) have demonstrated that the Ser/Thr kinase mTOR initiates myoblast differentiation by regulating the expression of *IGF2*. In addition, Zhang *et al.* (1998) have suggested that AP-2 may contribute to IGF-II overexpression in an embryonal skeletal muscle tumor (rhabdomyosarcoma).

Aims of the thesis

The objectives of this thesis were:

- To identify the causative mutation(s) for a major QTL in the pig influencing muscle growth, fat deposition and heart size located on SSC2p.
- To characterize the molecular mechanism(s) through which the mutation exerts its effects.

Methods

I. Transient transfection

This method can be used to determine if a DNA element is involved in transcriptional regulation of gene expression *e.g.* if it acts as promoter or enhancer. Firstly, the element of interest is cloned in a plasmid containing a reporter gene which expression can be easily assayed (*e.g.* luciferase, green fluorescent protein, chloramphenicol acetyl transferase). If the element is a putative promoter, it will be inserted in a plasmid containing a strong enhancer (*e.g.* SV40 enhancer). On the other hand, if the experimentator wants to test a supposed enhancer or silencer, it will be cloned in a plasmid containing a promoter. In this case, it is generally recommended to use the homologous promoter. Secondly, the plasmid is transfected into a suitable cell line. This can be done by a biochemical (*e.g.* cation lipid, calcium phosphate), physical (*e.g.* electroporation) or virus-mediated method. It is important to simultaneously transform the cells with a control vector (expressing a different reporter) to be able to monitor differential cell growth and transfection efficiency. Finally, the activity of the reporter is assayed after one to four days incubation and the observed reporter signal is normalized to the control.

II. Electrophoretic Mobility Shift Assay (EMSA)

EMSA is a standard biochemical *in vitro* method to detect protein-DNA interactions (Fried & Crothers, 1981). This assay is based on the fact that migration of DNA through a native polyacrylamide gel is retarded upon protein binding. First, a short double stranded DNA fragment (called the probe) is radioactively labelled. Second, the probe is incubated with proteins to allow DNA-protein complexes to form. Proteins from diverse origins can be used in EMSA *e.g.* nuclear or whole-cell extracts from cells or tissues (Dignam, Lebovitz & Roeder, 1983) and purified recombinant proteins. Third, the protein-DNA binding reactions are electrophoresed on a native polyacrylamide gel to separate free and protein-bound DNA. After autoradiography, the band corresponding to the DNA-protein complex appears higher on the gel compared to the free probe; the probe has also been “shifted” (Fig. 2). The migration of the DNA-protein complex depends mainly on the charge, shape and multimeric state of the protein. The specificity of the obtained complexes has to be tested by the addition of an excess of cold probe to the binding reaction. If the protein binds specifically it has the same affinity for the cold and for the radioactively labelled probe. Hence, both probes will compete for its binding and as the cold probe is in large molar excess there will be no protein left to bind to the labelled probe, which results in the disappearance of the complex.




Figure 2 Hypothetical EMSA. The free (unbound) probe as well as two specific and one unspecific complex are represented (modified from Carey & Smale, 2000)

The major advantages of EMSA are its simplicity and its high sensitivity. In addition, it allows the detection of complexes of different composition, each complex appearing as a band with a specific migration. Furthermore, EMSA gives the possibility to check the identity of proteins included in a complex by using antibodies. Hence, a specific antibody can be added to the protein-DNA binding reaction and its binding to the protein will result in an antibody-protein-DNA complex which gel migration will be even more retarded (this is called a supershift). Alternatively, the antibody can cover the DNA binding site of the protein and thereby prevent the formation of the complex, resulting in the disappearance of the shifted band (Carey & Smale, 2000).

III. DNase I Footprinting

DNase I footprinting allows the detection of protein-DNA interactions *in vitro* (Galas and Schmitz, 1978). This method is based on the principle that DNA regions bound by proteins are protected from digestion by DNase I. Basically, a double-stranded DNA probe corresponding to the region of interest is radioactively labelled on one end and used to set up two parallel reactions: one with proteins, the other without. After incubation, a specific amount of DNase I is added to both reactions so that each DNA molecule is cut only once. DNase I cuts randomly, and in the absence of proteins the probe will be digested in a series of labelled fragments ranging from one bp to full length probe. On the other hand, if DNA-protein complexes form, the DNA bound by the proteins will not be accessible to

the enzyme and this will result in the absence of DNA fragments of specific sizes. Both reactions are then run on a denaturing polyacrylamide gel to separate the DNA fragments according to their length. After autoradiography of the gel, the probe incubated without proteins will appear as a continuous series of bands. The probe incubated with proteins will also appear as a series of bands, but if protein-DNA complexes have formed the areas corresponding to the complexes will be devoid of bands. Those regions are called “footprints” (Carey & Smale, 2000). Usually, a Maxam-Gilbert sequencing reaction of the probe is run together with the DNase I digestions to enable the localization of the footprints (Fig. 3). The main advantage of this method is that it gives the approximate binding site of each protein binding to the probe. Furthermore, it is possible to analyse a quite long DNA region in a single experiment (the probes are generally at least 300 bp long).




Figure 3 Hypothetical DNase I footprinting experiment allowing the detection of two protected regions. Footprint 1 appears as a region devoid of bands whereas in footprint 2 the bands are only weakened compared to the ones from the probe incubated without proteins. A ladder (which is usually a Maxam- Gilbert A+G sequencing reaction) is electrophoresed together with the digested probes to allow localization of the footprints.

Results and discussion

I. Comparative sequence analysis of the *INS-IGF2-H19* gene cluster in pigs (Paper 1)

The aim of this work was to further characterize the region containing the mutation(s) causing the QTL. Here we report the sequence analysis of two pig contigs. The first one is 32 kb long and contains the five last exons of *TH* (Tyrosine hydroxylase) as well as the entire *INS* (insulin) and *IGF2* genes. The second one contains *H19* and covers 56 kb.

We started by characterizing the order and the structure of *INS*, *IGF2* and *H19* in pig and showed that they were identical to the ones in human. Hence, the gene order is as follows: *TH* - 1.9 kb - *INS* - 0.7 kb - *IGF2* - 88.1 kb - *H19*. *IGF2* is composed of ten exons (1-9 and 4b) that display high sequence identity between human and pig (Fig. 4).




Figure 4. Genomic structure of porcine *IGF2*. The ten exons of *IGF2* are represented as boxes, black boxes correspond to the translated exons. The four promoters of *IGF2* (P1-4) are represented by arrows.

Nezer *et al.* (1999) showed that the coding region of *IGF2* was identical between pigs with different QTL genotypes. We therefore suspected the causative mutation(s) to lie in (a) regulatory element(s). Such elements tend to be well conserved between species. This results from natural selection as individuals carrying mutations in a regulatory element might display erratic gene expression and lower fitness. Consequently, we compared our pig sequence with available human and mouse sequences to find these conserved regions. We report 59 evolutionary conserved elements (outside exons, promoters and simple repeats) in the *INS-IGF2* region and 38 in the *H19* region. Most of them have an unknown function but some have been assigned an important role in regulating the expression of *IGF2* in human and mouse *e.g.* DMR1, CTCF binding sites, endodermal enhancers (see introduction).

As expected from phylogenetic studies, the overall sequence similarity was higher between pig and human than between pig and mouse or human and mouse. The pig sequence displays an amazingly large number of CpG islands: nine in the *INS-IGF2* region and sixteen in the *H19* region. This can be put into relation with the imprinting of the region. Indeed, CpG islands are more often found associated with imprinted than with non-imprinted genes. The sequence is also characterized by its low abundance of interspersed repeats. Once again, this could be related to

the imprinting of *IGF2* and *H19* as the introduction of foreign sequence might perturb the complex regulatory mechanisms controlling their expression.

Another important part of this work was to characterize *IGF2* transcripts and promoter usage in different fetal and adult tissues. We found that *IGF2* transcription is tissue- and development-specific and that it can be initiated from four promoters (P1-4 located upstream of exons 1, 4, 5 and 6, respectively).

II. A regulatory mutation in *IGF2* causes a major QTL effect on muscle growth in the pig (Paper 2)

Nezer and co-workers (2003) refined the position of the QTL to a 250 kb-long interval between the markers 370SNP6/15 and SWC9 (located in the 3' untranslated region of *IGF2*). The only known paternally expressed genes mapping to this region were insulin and *IGF2*. Therefore, we decided to re-sequence 28.6 kb covering these two genes on 15 chromosomes which QTL status could be determined by progeny testing and marker-assisted segregation analysis. One of the chromosomes (H254) appeared to be recombinant and allowed us to localize the QTL downstream of the first exon of *IGF2*. Among the 258 polymorphisms differentiating the 15 chromosomes, we only found one SNP co-segregating perfectly with the QTL status of the chromosome. Therefore, this SNP, a G→A transition at position *IGF2*-intron 3-nt 3072, has to be the causative mutation. The wild type allele (G) is associated with lower muscle mass and was therefore named "q" while the mutant allele (A) causes higher muscle development and was called "Q". The quantitative trait nucleotide (QTN) is located in an evolutionary conserved CpG island of unknown function. Consequently, we set up EMSA and transient transfection experiments to uncover its mechanism of action. In addition, we studied the methylation status of the CpG island by bisulphite sequencing.

We carried out EMSA with nuclear extracts from three different cell types (C2C12 murine myoblasts, HepG2 human hepatocytes and HEK 293 human embryonic kidney cells) and three different 27 bp-long probes:

- q: wild-type probe
- Q: mutant probe
- q*: wild-type probe with a methylated CpG at the QTN. As methylation is important for expression of imprinted genes we designed this probe in order to test the influence of methylation on *in vitro* binding to the QTN.

We demonstrated the existence of a specific complex forming only with the wild-type probe but not with the mutant probe nor with the methylated probe.

We transfected C2C12 myoblast cells with reporter plasmids expressing firefly luciferase under the control of the thymidine kinase minimal promoter (*TK*) and a 578 bp-long fragment corresponding to the q or Q genotype at the QTN. After normalization, we found that the q insert doubles the basal TK transcription whereas the Q insert increases it seven times.




Figure 5 Results of transient transfection experiments carried out with reporter plasmids expressing firefly luciferase under the control of *TK* and an insert corresponding to the *q* (*q+TK*) or *Q* (*Q+TK*) allele at the QTN. Results were normalised to a Renilla luciferase control plasmid and are expressed as relative activities to a plasmid expressing firefly luciferase under the sole control of *TK*. The triple asterisk indicates that the differences observed between the three plasmids are highly significant ($P < 0.01$).

These results were quite difficult to conciliate with the results of the EMSA. For this reason, we replaced the *TK* promoter with *IGF2* promoter 3 (*P3*) and repeated the experiment. We choose *P3* because it is the most actively transcribed promoter in muscle cells and because it is influenced by the QTN *in vivo* (see below). This time, we found that *q* reduces the basal *P3* transcription with 70%, whereas *Q* only reduces it with 30%.




Figure 6 Results of transient transfections carried out like in Fig. 6 but plasmids express luciferase under the control of the *P3* instead of *TK*.

Taken together with the EMSA these new results suggest that the QTN abrogates the binding of a repressor to a *cis*-element. In addition, our transient transfection experiments illustrate how important it is to use a homologous rather than a heterologous promoter in this kind of experiments.

We analyzed the methylation of the CpG island containing the QTN and found that it is independent from the genotype at the QTN and from the parental origin of the allele. However, we found that it is tissue-specific. Hence, on average, 26% of the CpG dinucleotides are methylated in liver but only 3.4% are methylated in skeletal muscle. Interestingly, the effect of the QTN is observed in muscle *i.e.* in a

non-methylated tissue where the putative repressor is able to bind, but no effect is seen in liver which is more methylated and where the putative repressor might consequently not be able to bind so efficiently (according to the EMSA results). It would be very exciting to analyze the situation in other tissues to check if this association between methylation status and QTN effect holds.

We quantified the expression of *IGF2* *in vivo* and found a significantly higher expression in postnatal muscle samples from QQ and Q^{pat}q^{mat} animals compared to q^{pat}Q^{mat} and qq animals. A weaker (but significant) difference could also be observed in postnatal heart samples but not in postnatal liver nor in any tested prenatal tissue sample. Furthermore, we showed that *IGF2* transcription was increased from all three promoters located downstream of the QTN (*i.e.* P2-4).

Finally, we genotyped the progeny of 13 heterozygous sires (Qq) and of 50 homozygous sires (QQ or qq) and used this data in segregation analyses. We found evidence for segregation in all heterozygous families but we could not find any indication of segregation among progeny sired by homozygous males. Furthermore, Jungerius *et al.* (2005) showed that the QTN also controls the QTL for backfat thickness found in a Meishan x European Whites cross. In conclusion, we demonstrated that the SSC2p QTL is caused by a G→A transition at position *IGF2*-intron 3-nt 3072 and that this mutation influences *IGF2* expression. Hence, we showed that, in addition to its well-known fetal role, *IGF2* is involved in postnatal muscle development.

III. *IGF2* antisense transcript expression in porcine postnatal muscle is affected by a quantitative trait nucleotide in intron 3 (Paper 3)

The aim of this study was to search for an *IGF2* antisense (*IGF2-AS*) gene in pig, and upon its existence to:

- Characterize and quantify its transcript(s).
- Examine its imprinting status.
- Determine whether its expression was influenced by the *IGF2* QTN.

We have shown by RT-PCR and RNase protection assay (RPA) that *IGF2-AS* indeed exists in pig. Furthermore, we have shown that it has two different transcription start sites; a major site located around *IGF2* intron4-nt70 and a minor site located approximately at *IGF2* intron3-nt2294 (RPA results) or intron3-nt2205 (5' RACE results). The 3' end of the transcripts was mapped to position *IGF2* intron2-nt1236 by RACE. We found three different transcripts originating at the major start site. These transcripts contain from three to five exons and share all the same first and last exons (Fig. 7).




Figure 7. Genomic structure of porcine *IGF2* and multiple *IGF2-AS* transcripts (a-d). Exons are represented as boxes, black boxes correspond to the translated exons. Promoters are represented by arrows

Hence, we can conclude that the structure of *IGF2-AS* is not well conserved between pig, human and mouse as this gene only has three exons in human and four in mouse. However, some of the exons are quite well conserved between species (Table 1).

Table1. Sequence identities between *IGF2-AS* exons in pig and human or mouse.

Pig exon	Human exon	Mouse exon	% Identity
1	1		72
2		2	60
5	3		63

Northern blot analyses revealed the existence of three transcripts in fetal muscle (4.7 kb, 3.3 kb and 2.1 kb), two in fetal liver (3.5 kb and 2.1 kb) and one in fetal kidney (3.3 kb). Surprisingly, the shortest band observed on the northern blot is longer than the longest transcript predicted by the RT-PCR and 3' RACE results. This could result from preferential amplification of short truncated transcripts by the nested RACE PCR or from a real heterogeneity of the transcripts.

Next, we examined the imprinting status of *IGF2-AS* in liver and muscle samples from fetal, 3-weeks- and 4-months-old piglets. This was done by sequencing an A to C transversion at IGF2-AS exon2-nt32 which allowed us to discriminate between Q and q alleles at the QTN. We found that *IGF2-AS* is imprinted and only expressed from the paternal allele. This reflects the status at other imprinted loci as most antisense transcripts found in imprinted genes are maternally silenced. However, we should note that in muscle of 4-months-old pigs

we could detect some transcription from maternal origin which indicates that imprinting is partially released.

Finally, we used real-time PCR analysis to quantify *IGF2-AS* transcripts in muscle and liver from fetal, 3-weeks- and 4-months old pigs carrying the q or Q allele at the QTN. Firstly, we found that the expression of *IGF2-AS* decreases noticeably after birth. Secondly, we found that in 3-weeks- and 4-months-old pig muscle it depends on the genotype at the QTN. Indeed, at these stages, *IGF2-AS* expression was significantly higher in Q than in q muscle samples. Hence, the putative repressor binding at the QTN seems to influence both *IGF2* and *IGF2-AS* expression.

The function of *IGF2-AS* is still unknown, but it has been suggested that it could take part in the regulation of *IGF2* expression. Indeed, it is noteworthy that in pig as well as in human, the first and the last exon of *IGF2-AS* overlap part of *IGF2* exon 4 and the entire exon 3, respectively. Consequently, *IGF2-AS* could interfere with transcripts originating from P1 and P2.

IV. Molecular Characterization of a Region in *IGF2* Intron 3 harbouring a Quantitative Trait Nucleotide affecting Muscle Growth in the Pig (Paper 4)

The aim of this study was to:

- Determine the binding site of the transcription factor binding to the QTN.
- Characterize the CpG island containing the QTN.
- Search for polymorphisms in the CpG island in human.

We used EMSA to determine which nucleotides were important for the binding of the putative repressor described in paper 2. Firstly, we performed EMSA with a series of mutated probes to determine if these mutations could abolish formation of the specific complex obtained with the wild-type probe. Secondly, we used the mutated oligonucleotides in a competition assay to determine if they were still able to compete against the wild-type probe. Taking these results together, we found that the core binding site of the transcription factor is: 5'-GCTCG-3'. New database searches did not reveal any factor with similar binding capacities.

DNase I footprinting of the 333 bp surrounding the QTN revealed two protected regions, FP1 and FP2:

- FP1 covers ~50 bp (from nucleotide position ~3027 to ~3076) and includes the core binding site of the putative repressor and a perfect consensus AP-2 binding site.
- FP2 is a ~ 30 bp-long footprint located ~20 bp upstream of FP1 (from nucleotide position ~2981 to ~3008) and covers a putative Sp1 binding site.

AP-2 has previously been shown to regulate *IGF2* transcription from P3 and it would be particularly interesting to confirm its binding to FP2. Even more interesting would be to know if it binds DNA as a heteromer with the putative repressor. Hence, if they bind together, one could try to purify the repressor by co-immunoprecipitating it with AP-2.

Comparative sequence analyses of the CpG island containing the QTN have revealed a high sequence conservation between pig and human. This led us to the hypothesis that the human DNA sequence could contain *cis*-elements involved in muscle development, as is the case in pig. Therefore, we resequenced this region in individuals with low versus high muscle mass. We discovered three SNPs and one insertion/deletion. Interestingly, one of the mutations (C→T, at position *IGF2*-intron 3-3462) lies in the putative AP-2 site included in FP2. Consequently, we analysed the *in vitro* binding capacity of this site by running EMSA with a wild-type and a mutant probe of the region. We were able to detect binding of specific complexes with similar mobility using both wild-type and mutant sequences. It would be very interesting to complement this experiment by a supershift assay with AP-2-specific antibodies to confirm the involvement of this transcription factor.

Future prospects

This thesis summarizes the work that led to the identification of the causative mutation for a QTL influencing muscle development, fat deposition and heart size in pig. In addition, it presents how we have started to uncover the molecular mechanisms by which this QTN mediates its effects. We have shown that the mutation abrogates the binding of a putative repressor element, which results in increased expression of *IGF2* and *IGF2-AS*. We have also demonstrated that other transcription factors bind DNA in the immediate vicinity of this repressor. The obvious next step in this project will be to clone and characterize this repressor. Different methods could be considered to achieve this goal *e.g.* one-hybrid screen, *in vitro* expression library screening, biochemical purification. In order to choose the most appropriate approach, it is important to collect as much information as possible on this transcription factor and on its possible interactions with the neighbouring DNA-binding factors. It is for example essential to know if it binds DNA by itself or as a heteromer (as could be suspected from the DNase I footprinting results). Indeed, some of the methods cited above are only capable to deal with proteins binding as monomer, homodimer or homopolymer. In addition, identifying a known factor binding DNA together with the repressor could be extremely useful; antibodies against this factor could be used to co-immunoprecipitate both factors as a first step towards purification of the repressor.

The identification of the gene coding for a transcription factor might be a difficult task, but it would be worth the effort as this repressor could have fascinating therapeutic uses in the future. Indeed, it could be inactivated to increase the expression of *IGF2* in specific tissues. Our study has demonstrated that it is active in skeletal muscle and heart but not in liver. In addition, it may also be active in adipocytes as the *IGF2*-QTL also influences backfat thickness. Hence, one could imagine to inactivate it in order to increase the muscle mass of patients suffering from muscular degenerative diseases. Furthermore, it could be transiently inactivated in patients confined in bed to avoid the muscle loss accompanying long periods of inactivity. In addition, if its activity is confirmed in adipocytes, it could even be used to treat obese patients.

Finally, the identification of the causative mutation for the *IGF2*-QTL makes it very easy to select pigs with the favourable Q allele to breed for the next generations and hence to fix the mutation in populations where it is present. In addition, it will also facilitate the introgression of the mutant allele in pig breeds where it is absent. Indeed, when the introgression of a favourable gene variant is based on linked markers there is always a risk to lose it because of a recombination between the markers and the actual causative mutation. This problem has now been eliminated and makes the *IGF2*-QTL a very attractive candidate for introgression into certain commercial populations.

References

- Ainscough, J.F., John, R.M., Barton, S.C. & Surani, M.A. 2000. A skeletal muscle-specific mouse *Igf2* repressor lies 40 kb downstream of the gene. *Development* 127, 3923-3930.
- Andersson L. 2001. Genetic Dissection of Phenotypic Diversity in Farm Animals. *Nature Reviews Genetics* 2, 130-138.
- Andersson, L., Haley, C.S., Ellegren, H., Knott, S.A., Johansson, M., Andersson, K., Andersson-Eklund, L., Edfors-Lilja, I., Fredholm, M., & Hansson, I. 1994. Genetic mapping of quantitative trait loci for growth and fatness in pigs. *Science* 263, 1771-1774.
- Andersson-Eklund, L., Marklund, L., Lundstrom, K., Haley, C.S., Andersson, K., Hansson, I., Moller, M. & Andersson, L. 1998. Mapping quantitative trait loci for carcass and meat quality traits in a wild boar x Large White intercross. *Journal of Animal Science* 76, 694-700.
- Bae, S.K., Bae, M.H., Ahn, M.Y., Son, M.J., Lee, Y.M., Bae, M.K., Lee, O.H., Park, B.C. & Kim, K.W. 1999. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. *Cancer Research* 59, 5989-5994.
- Bartolomei, M.S., Zemel, S. & Tilghman, S.M. 1991. Parental imprinting of the mouse H19 gene. *Nature* 351, 153-155.
- Bell, A.C. & Felsenfeld, G. 2000. Methylation of a CTCF-dependent boundary controls imprinted expression of the *Igf2* gene. *Nature* 405, 482-485.
- Brannan, C.I. & Bartolomei, M.S. 1999. Mechanisms of genomic imprinting. *Current Opinion in Genetics & Development* 9, 164-170.
- Carey, M. & Smale, S. 2000. *Transcriptional Regulation in Eukaryotes* Cold Spring Harbor Laboratory Press, New York, USA.
- Cohick, W.S. & Clemmons, D.R. 1993. The insulin-like growth factors. *Annual Review of Physiology* 55, 131-153.
- Constancia, M., Pickard, B., Kelsey, G. & Reik, W. 1998. Imprinting mechanisms. *Genome Research* 8, 881-900.
- DeChiara, T.M., Robertson, E.J. & Efstratiadis, A. 1990. A growth-deficient phenotype in heterozygous mice carry an insulin-like growth factor II gene disrupted by targeting. *Nature* 344, 78-80.
- DeChiara, T.M., Robertson, E.J. & Efstratiadis, A. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. *Cell* 64, 849-859.
- Delaval, K. & Feil, R. 2004. Epigenetic regulation of mammalian genomic imprinting. *Current Opinion in Genetics & Development* 14, 188-195.
- Dignam, J.D., Lebovitz, R.M. & Roeder, R.G. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Research* 11, 1475-1489.
- Du, M., Beatty, L., Zhou, W., Lew, J., Schoenherr, C., Weksberg, R. & Sadowski, P. 2003. Insulator and silencer sequences in the imprinted region of human chromosome 11p15.5. *Human Molecular Genetics* 12, 1927-1939.
- Dupont, J., Pierre, A., Froment, P. & Moreau, C. 2003. The insulin-like growth factor axis in cell cycle progression. *Hormone and Metabolic Research* 35, 740-750.
- Eden, S., Constancia, M., Hashimshony, T., Dean, W., Goldstein, B., Johnson, A.C., Keshet, I., Reik, W. & Cedar, H. 2001. An upstream repressor element plays a role in *Igf2* imprinting. *The EMBO Journal* 20, 3518-3525.
- Erbay, E., Park, I.H., Nuzzi, P.D., Schoenherr, C.J. & Chen, J. 2003. IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. *The Journal of Cell Biology* 163, 931-936.
- Fazzari, M. & Greally, J. 2004. Epigenomics: beyond CpG islands *Nature Reviews Genetics* 5, 446-455.

- Feinberg, A.P., Cui, H. & Ohlsson, R. 2002 DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. *Seminars in Cancer Biology* 12, 389-398.
- Ferguson-Smith, A.C. & Surani, M.A. 2001. Imprinting and the epigenetic asymmetry between parental genomes. *Science* 293, 1086-1089.
- Florini, J.R., Magri, K.A., Ewton, D.Z., James, P.L., Grindstaff, K. & Rotwein, P.S. 1991. "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. *The Journal of Biological Chemistry* 266, 15917-1523.
- Fowden, A.L. 2003. The insulin-like growth factors and feto-placental growth. *Placenta*. 24, 803-812.
- Fried, M. & Crothers, D.M. 1981. Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis. *Nucleic Acids Research*, 9, 6505-6525.
- Froesch, E.R., Schmid, C., Schwander, J. & Zapf, J. 1985. Actions of insulin-like growth factors. *Annual Review of Physiology* 47, 443-467.
- Galas, D.J. & Schmitz, A. 1978. DNase footprinting: a simple method for the detection of protein-DNA binding specificity. *Nucleic Acids Research* 5, 3157-3170.
- Gardiner-Garden, M. & Frommer, M. 1987. CpG islands in vertebrate genomes. *Journal of Molecular Biology* 196, 261-282.
- Georges, M. & Andersson, L. 1996. Livestock Genomics Comes of Age. *Genome Research* 6, 907-921.
- Goureau, A., Yerle, M., Schmitz, A., Riquet, J., Milan, D., Pinton, P., Frelat, G. & Gellin, J. 1996. Human and porcine correspondence of chromosome segments using bidirectional chromosome painting. *Genomics* 36, 252-262.
- Hark, A.T., Schoenherr, C.J., Katz, D.J., Ingram, R.S., Leverage, J.M. & Tilghman, S.M. 2000. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. *Nature* 405, 486-489.
- Ishihara, K., Hatano, N., Furuumi, H., Kato, R., Iwaki, T., Miura, K., Jinno, Y. & Sasaki, H. 2000. Comparative genomic sequencing identifies novel tissue-specific enhancers and sequence elements for methylation-sensitive factors implicated in Igf2/H19 imprinting. *Genome Research* 10, 664-671.
- Jaenish, R. & Bird, A. 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nature Genetics Supplement* 33, 245-154.
- Jeon, J.T., Carlborg, O., Tornsten, A., Giuffra, E., Amarger, V., Chardon, P., Andersson-Eklund, L., Andersson, K., Hansson, I., Lundstrom, K. & Andersson, L. 1999. A paternally expressed QTL affecting skeletal and cardiac muscle mass in pigs maps to the IGF2 locus. *Nature Genetics* 21, 157-158.
- Jones, J.I. & Clemmons, D.R. 1995. Insulin-like growth factors and their binding proteins: biological actions. *Endocrine Reviews* 16, 3-34.
- Jones, P. 1999. The DNA methylation paradox. *Trends in Genetics* 15, 34-37.
- Jungerius, B., Van Laere, A.S., te Pas, M., van Oost, B., Andersson, L. & Groenen, M. 2005. The IGF2-intron 3-G3072A substitution explains a major imprinted QTL effect on backfat thickness in a Meishan X European white pig intercross. *Genetical Research in press*.
- Kanduri, C., Holmgren, C., Pilartz, M., Franklin, G., Kanduri, M., Liu, L., Ginjala, V., Ulleras, E., Mattsson, R. & Ohlsson, R. 2000a. The 5' flank of mouse H19 in an unusual chromatin conformation unidirectionally blocks enhancer-promoter communication. *Current Biology* 10, 449-457.
- Kanduri, C., Pant, V., Loukinov, D., Pugacheva, E., Qi, C.F., Wolffe, A., Ohlsson, R. & Lobanekov, V.V. 2000b. Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. *Current Biology* 10, 853-856.
- Kitsberg, D., Selig, S., Keshet, I. & Cedar, H. 1993. Replication structure of the human beta-globin gene domain. *Nature* 366, 588-590.

- Labosky, P.A., Barlow, D.P. & Hogan, B.L. 1994. Mouse embryonic germ (EG) cell lines: transmission through the germline and differences in the methylation imprint of insulin-like growth factor 2 receptor (Igf2r) gene compared with embryonic stem (ES) cell lines. *Development* 120, 3197-3204.
- Lee, S., Park, U. & Lee, Y.I. 2001. Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites. *Virology* 283,167-177.
- Lee, Y.I., Lee, S., Lee, Y., Bong, Y.S., Hyun, S.W., Yoo, Y.D., Kim, S.J., Kim, Y.W. & Poo, H.R. 1998. The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4. *Oncogene* 16, 2367-2380.
- Leighton PA, Saam JR, Ingram RS, Stewart CL, Tilghman SM. 1995. An enhancer deletion affects both H19 and Igf2 expression. *Genes & Development* 9, 2079-2089.
- Li, E., Beard, C. & Jaenisch, R. 1993. Role for DNA methylation in genomic imprinting. *Nature* 366, 362-365.
- Louvi, A., Accli, D. & Efstratiadis, A. 1997. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. *Developmental Biology* 189, 33-48.
- McKinnon, T., Chakraborty, C., Gleeson, L.M., Chidiac, P. & Lala, P.K. 2001. Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. *The Journal of Clinical Endocrinology and Metabolism* 86, 3665-3674.
- Minniti, C.P., Kohn, E.C., Grubb, J.H., Sly, W.S., Oh, Y., Muller, H.L., Rosenfeld, R.G. & Helman, L.J. 1992. The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. *The Journal of Biological Chemistry* 267, 9000-9004.
- Mohan, S. & Baylink, D.J. 2002. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. *Journal of Endocrinology* 175, 19-31.
- Nezer, C., Collette, C., Moreau, L., Brouwers, B., Kim, J.J., Giuffra, E., Buys, N., Andersson, L. & Georges, M. 2003. Haplotype sharing refines the location of an imprinted quantitative trait locus with major effect on muscle mass to a 250-kb chromosome segment containing the porcine IGF2 gene. *Genetics* 165, 277-285.
- Nezer, C., Moreau, L., Brouwers, B., Coppeters, W., Detilleux, J., Hanset, R., Karim, L., Kvasz, A., Leroy, P. & Georges, M. 1999. An imprinted QTL with major effect on muscle mass and fat deposition maps to the IGF2 locus in pigs. *Nature Genetics* 21, 155-156.
- O'Dell, S.D. & Day, I.N. 1998. Insulin-like growth factor II (IGF-II). *The International Journal of Biochemistry & Cell Biology* 30, 767-771.
- Oksbjerg, N., Gondret, F. & Vestergaard, M. 2004. Basic principles of muscle development and growth in meat-producing mammals as affected by the insulin-like growth factor (IGF) system. *Domestic Animal Endocrinology* 27, 219-240.
- Paldi, A., Gyapay, G. & Jami, J. 1995. Imprinted chromosomal regions of the human genome display sex-specific meiotic recombination frequencies. *Current Biology* 5, 1030-1035.
- Rand, E. & Cedar, H. 2003. Regulation of Imprinting: A Multi-Tiered Process. *Journal of Cellular Biochemistry* 88, 400-407.
- Reik, W. & Walter, J. 2001a. Evolution of imprinting mechanisms: the battle of the sexes begins in the zygote. *Nature Genetics* 27, 255-256.
- Reik, W. & Walter, J. 2001b. Genomic imprinting: parental influence on the genome. *Nature Reviews Genetics* 2, 21-32.
- Rietveld, L.E., Koonen-Reemst, A.M., Sussenbach, J.S. & Holthuisen, P.E. 1999. Dual role for transcription factor AP-2 in the regulation of the major fetal promoter P3 of the gene for human insulin-like growth factor II. *The Biochemical Journal* 338, 799-806.

- Rodenburg, R.J., Holthuisen, P.E. & Sussenbach, J.S. 1997. A functional Sp1 binding site is essential for the activity of the adult liver-specific human insulin-like growth factor II promoter. *Molecular Endocrinology* 11, 237-250.
- Sleutels, F., Zwart, R. & Barlow, D.P. 2002. The non-coding Air RNA is required for silencing autosomal imprinted genes. *Nature* 415, 810-813.
- Srivastava, M., Hsieh, S., Grinberg, A., Williams-Simons, L., Huang, S.P. & Pfeifer, K. 2000. H19 and Igf2 monoallelic expression is regulated in two distinct ways by a shared cis acting regulatory region upstream of H19. *Genes & Development* 14, 1186-1195.
- Strachan, T. & Read, A. 1999. *Human molecular genetics 2*, BIOS Scientific Publishers Ltd, Oxford, UK.
- Sussenbach, J.S. 1989. The gene structure of the insulin-like growth factor family. *Progress in Growth Factor Research* 1, 33-48.
- Thakur, N., Tiwari, V.K., Thomassin, H., Pandey, R.R., Kanduri, M., Gondor, A., Grange, T., Ohlsson, R. & Kanduri, C. 2004. An antisense RNA regulates the bidirectional silencing property of the Kcnq1 imprinting control region. *Molecular and Cellular Biology* 24, 7855-7862.
- Thomas, B.J. & Rothstein, R. 1991. Sex, maps, and imprinting. *Cell* 64, 1-3.
- Tilghman, S.M. 1999. The sins of the fathers and mothers: genomic imprinting in mammalian development. *Cell* 96, 185-193.
- van Dijk, M.A., Rodenburg, R.J., Holthuisen, P. & Sussenbach, J.S. 1992. The liver-specific promoter of the human insulin-like growth factor II gene is activated by CCAAT/enhancer binding protein (C/EBP). *Nucleic Acids Research* 20, 3099-3104.
- van Dijk, M.A., van Schaik, F.M., Bootsma, H.J., Holthuisen, P. & Sussenbach, J.S. 1991. Initial characterization of the four promoters of the human insulin-like growth factor II gene. *Molecular and Cellular Endocrinology* 81, 81-94.
- Wilkins, J.F. & Haig, D. 2003. What good is genomic imprinting: the function of parent-specific gene expression. *Nature Reviews Genetics* 4, 359-368.
- Wood, T.L. 1995. Gene-targeting and transgenic approaches to IGF and IGF binding protein function. *The American Journal of Physiology* 269, E613-622.
- Zatkova, A., Rouillard, J.M., Hartmann, W., Lamb, B.J., Kuick, R., Eckart, M., von Schweinitz, D., Koch, A., Fonatsch, C., Pietsch, T., Hanash, S.M. & Wimmer, K. 2004. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. *Genes, Chromosomes & Cancer* 39, 126-137.
- Zhang, L., Zhan, S., Navid, F., Li, Q., Choi, Y.H., Kim, M., Seth, P. & Helman, L.J. 1998. AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma. *Oncogene* 17, 1261-1270.

ACKNOWLEDGEMENTS

I would like to take thank the following persons:

My supervisors:

Leif Andersson. Thank you for giving me the chance to work in the fascinating field of molecular genetics; but most of all, thank your enthusiasms, your optimism and for the great independence you gave me.

Göran Andersson. Thank you for always taking the time to answer my questions and for making me see the world from your transcriptional point of view.

Valérie Amarger. C'est toi qui m'as mis le pied à l'étrier, merci!

The past and present members of the lab:

Gabriella Lindgren, Carl-Gustaf Thulin, Stefan Marklund, Siw Johansson, Elisabetta Giuffra, Jin-Tae Jeon, Anna Törnsten, Göran Hjälms, Anna-Karin Fridolfsson, Maria Moller, Örjan Carlborg, Gabriella Nyman, Teresa Casals, Jessica Petersson

Amélie Johansson. I am looking forward to the next ISAG conference.

Ana Fenandez and Meiyang Fang. You saved me each time I was looked out of my office.

Carolyn Fitzsimmons. I will miss these Ph.D. student parties.

Emmanuelle Bourneuf. You have a great sense of humor (et merci d'avoir sauvé mon gel!)

Erik Bongcam-Rudloff. You saved my computer from falling out through the window.

Frida Berg. Where are you taking this amazing energy from?

Lina Jacobsson and Susanne Kerje. I would never have made it to the Big Apple without you.

Martin Braunschweig. The *IGF2* group was not the same anymore after you left

My brother, Ben. It was great having you here for four month (même si Voldo s'est pris quelque raclées).

My office-mate, Hee-Bok Park. I enjoyed sharing the office with you and the "little guy", good luck in Malmö.

Nicolette Sammon Hillbertz. I will miss the hugs, the week-ends at the countryside, the dogs and all the rest.

Sonchita Bagchi. You are a real sunshine.

The first person I met when I arrived, Gerli Pielberg. You have been a real friend during these five years. Thank you for defending your thesis two month before me in order to figure out all the administrative mess!

The new generation of Ph.D. students: Ullrika Gunnarsson, Per Wahlberg and Ellen Markljung. Time is flying so fast that you will soon be writing your own little book; enjoy pipetting as long as it lasts!

Ulla Gustafson and Gudrun Wieselander. The lab would not survive without you.

All the Swedes. Tack för att ni hjälpte mig att lära mig språket!

All the people in my “adoptive” labs:

Cihan Cetinkaya, Natalie von der Lehr and Fuad Bahram. I will never forget that the cells are “my children”.

Susanna Tronnarsjö. You made me discover the fascinating world of the budding yeasts.

Beat Bornhauser. Thank you for always having the time to show me how to use the nice machines you have down there.

The AgriFunGen program at SLU.

I am grateful for my founding, but also for all the interesting courses and for the great meetings!

Ma famille et mes amis.

Merci pour tous ces bons moments passés ensemble pendant mes vacances et pour vos encouragements pendant le restant de l’année.